A new acquisition agreement between OPKO Health, Inc. and Israeli medical device company Inspiro Medical Ltd. will incorporate a new drug delivery platform into OPKO’s repertoire. Inspiro’s Inspiromatic™ is a dry powder inhaler that can deliver small or large molecule drugs to treat respiratory diseases. “We are pleased to add this next generation inhaler to OPKO’s growing product portfolio,” stated Phillip Frost, M.D., OPKO’s CEO and Chairman, in a press release from OPKO. “We expect this innovative device to play a valuable role in the improvement of therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis and other respiratory diseases.”
MRSA is a serious threat to CF patients. Get more information about [adrotate banner=”75″].
Dry-powder inhalers are an attractive alternative to nebulizers to deliver cystic fibrosis treatment. It is more convenient and time-efficient for patients to inhale dry-powder medication than wet aerosols. Nebulizers need a compressor unit or pressurized air if they are jet-type and electricity if they are unltrasonic, which largely immobilize the patient. What’s more, only approximately 1-32% of the intended dose reaches patients lungs when delivered via nebulizer. Studies have demonstrated that at least 40% of the intended dose from dry-powder inhalers is emitted, and the duration of administration of medication can decrease from at least 20 minutes to less than a minute. Therefore, not only are dry-powder inhalers more efficient, but also they may increase patient comfort, making cystic fibrosis therapy more effective overall.
Inspiromatic™ is designed for optimized delivery and enhanced patient compliance monitoring. An internal microcontroller, flow sensor controls, and micro-pump technology dispense drug particles in the correct dose at the right speed to prevent the need for forceful inhalation. Upon inhalation, a green or red light flashes to alert the patient if they properly inhaled, and a beep is sounded once the dose has been delivered. A built-in logger stores patient use data until physicians meet and evaluate the patient’s health.
“We are extremely proud of Inspiro’s success in bringing our smart Inspiromatic™ respiratory drug-delivery device to market,” said Nimrod Kaufmann, CEO and Co-Founder of Inspiro. “With Inspiro now a part of OPKO, we will be able to help more people faster. Inspiro joining OPKO is a big win for the shareholders of both Inspiro and OPKO, as well as good news for our patients and physicians.”